J.P. Morgan’s Salveen Richter Reiterates Buy on Teva, Citing TEV-408 Phase 2a Success and Pipeline-in-a-Product Potential
I'm LongbridgeAI. Here is the key information I extractedTeva Pharmaceutical, the Healthcare sector company, was revisited by a Wall Street analyst yesterday. Analyst Salveen Richter from Goldman Sachs maintained a Buy rating on the stock and has a $50.00 price target.
Salveen Richter has given his Buy rating due to a combination of factors tied to Teva’s emerging innovative pipeline and recent clinical progress. He views the new Phase 2a results for TEV-408 in celiac disease as a key validation point, showing meaningful protection against gluten-driven intestinal injury with no new safety concerns, in an area where approved therapies are lacking.
Richter also highlights that TEV-408 appears to have broad potential beyond celiac disease, building on earlier positive data in vitiligo and suggesting a pipeline-in-a-product profile that could differentiate Teva from competitors. He frames this data as part of Teva’s solid execution on an expanding R&D portfolio and a series of upcoming catalysts, which, in his view, improve the company’s long-term growth outlook even before IL-15 programs are explicitly reflected in his financial model.
According to TipRanks, Richter is a 5-star analyst with an average return of 13.4% and a 51.05% success rate. Richter covers the Healthcare sector, focusing on stocks such as Ionis Pharmaceuticals, Vertex Pharmaceuticals, and Moderna.